Last checked at 8 Jul 2021 14:41
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing (Note 1) | J.P. Morgan Securities LLC |
Company dealt in | AON plc |
Class of relevant security to which the dealings being disclosed relate (Note 2) | US$0.01 ordinary shares |
Date of dealing | 07 July 2021 |
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
| Long | Short | ||||
| Number |
| (%) | Number |
| (%) |
(1) Relevant securities | 6,836,924 3.03 | 2,153,322 0.95 | ||||
(2) Derivatives (other than options) | 1,848,216 0.82 | 81,872 0.04 | ||||
(3) Options and agreements to purchase/sell | 166,900 0.07 | 376,500 0.17 | ||||
Total | 8,852,040 3.92 | 2,611,694 1.16 | ||||
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale |
Number of relevant securities |
Price per unit (USD)
(Note 5) |
Purchase (New Borrow)
Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase
Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale | 13,500
100 44 100 1 274 103 4 15 52 48 5,239 93 13 9 14 4 4 46 565 2 5 13 16 3 516 40 67 48 4 3 6 1 50 50 100 129 300 503 32 364 100 78 8 3 2 11
200 200 200 30 6,323 6 34 101 81 565 200 3 3 50 47 200 300 503 35 200 78 100 2 2 11 11 | N/A
239.4700 USD 239.4234 USD 239.4000 USD 239.3200 USD 239.2886 USD 239.2600 USD 239.1550 USD 239.1150 USD 239.0888 USD 239.0867 USD 239.0500 USD 239.0341 USD 239.0331 USD 239.0044 USD 238.9743 USD 238.9700 USD 238.9300 USD 238.9176 USD 238.8621 USD 238.7500 USD 238.7300 USD 238.7212 USD 238.6825 USD 238.6400 USD 238.6081 USD 238.5763 USD 238.5460 USD 238.5315 USD 238.4950 USD 238.4667 USD 238.4600 USD 238.4500 USD 238.4472 USD 238.4340 USD 238.4200 USD 238.4113 USD 238.3083 USD 238.3072 USD 238.0650 USD 238.0436 USD 237.9300 USD 237.7200 USD 237.6825 USD 237.5900 USD 237.3750 USD 237.0641 USD
239.4700 USD 239.4000 USD 239.2600 USD 239.1150 USD 239.0500 USD 239.0033 USD 238.9900 USD 238.9651 USD 238.9650 USD 238.8621 USD 238.7400 USD 238.5600 USD 238.4667 USD 238.4472 USD 238.4400 USD 238.4200 USD 238.3083 USD 238.3072 USD 237.9800 USD 237.9300 USD 237.7200 USD 237.4600 USD 237.3850 USD 237.3750 USD 237.0850 USD 237.0641 USD |
(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD | Nature of transaction (Note 6) | Number of relevant securities (Note 7) | Price per unit (USD) (Note 5) |
|
Equity Swap | Decrease Long
Increase Long | 503
11 300 | 238.3072 USD
237.0850 USD 238.3083 USD |
|
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option | Writing, selling, purchasing, varying etc. | Number of securities to which the option relates (Note 7) | Exercise price (USD) | Type, e.g. American, European etc. | Expiry date | Option money paid/received per unit (Note 5) (USD) |
|
|
|
|
|
|
|
(ii) Exercising
Product name, e.g. call option | Number of securities | Exercise price per unit (Note 5) |
|
|
|
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction (Note 8) | Details | Price per unit (if applicable) (Note 5) |
|
|
|
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any
other person relating to the voting rights of any relevant securities under any option referred to on this
form or relating to the voting rights or future acquisition or disposal of any relevant securities to which
any derivative referred to on this form is referenced. If none, this should be stated.
None
Is a Supplemental Form 8 attached? (Note 9) Yes
Date of disclosure | 08 July 2021 |
Contact name | Alwyn Basch |
Telephone number | 0207 742 7407 |
If a connected EFM, name of offeree/offeror with which connected | N/A |
If a connected EFM, state nature of connection (Note 10) | N/A |
SUPPLEMENTAL FORM 8
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1 AND RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DETAILS OF OPEN POSITIONS
(This form should be attached to Form 8.1(a) & (b)(i), Form 8.1(b)(ii) or Form 8.3, as appropriate)
OPEN POSITIONS (Note 1)
Product name, e.g. call option | Written, or purchased | Number of relevant securities to which the option or derivative relates | Exercise price (Note 2) (USD) | Type, e.g. American, European etc. | Expiry date |
Call Option Call Option Call Option Call Option Put Option Call Option Put Option Call Option Put Option Call Option Call Option Call Option Call Option Put Option | Written Written Written Written Written Written Written Purchased Written Purchased Purchased Purchased Purchased Written | 46,200 71,700 77,400 104,700 600 3,100 44,000 13,800 8,200 72,000 54,200 26,600 300 20,600 | 270.00 270.00 270.00 270.00 240.00 270.00 230.00 240.00 230.00 260.00 260.00 260.00 240.00 250.00 | American American American American American American American American American American American American American American | 17/12/2021 17/12/2021 17/12/2021 17/12/2021 15/10/2021 17/12/2021 15/10/2021 16/07/2021 16/07/2021 17/12/2021 15/10/2021 16/07/2021 15/10/2021 17/12/2021 |
Notes
1. Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.
2. For all prices and other monetary amounts, the currency must be stated.
For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.